We are a platform offering superior molecular diagnostics closer to point of need, thanks to our silicon nanopore single-molecule sensor.
We bring precision diagnostics to everyone,
where and when they need it.
Two breakthrough platforms in development are powered by our unique silicon nanopore technology
Sample Prep, Amplification, Measurement
Sensitive, specific and fast sample-to-answer testing on one device with multi-modal and multiplexed capabilities
Combining genomics and epigenetics in a single assay to interrogate long, continuous spans of the genome with single-molecule precision
Our unique platforms can simultaneously analyze nucleic acids, proteins and small molecules, all in the same run.
Human & pathogen DNA & RNA
Full sized proteins & antibodies
Hormones, sugars, peptides
This is proprietary and dramatically changes the economics of testing for almost anything, and not just DNA: DNA, RNA, proteins, small molecules, it could test any of those things.
-Vinod Khosla, Khosla Ventures
Advancements in modern agriculture are increasingly driven by innovations in biology, data science, and digitization. Technologies like this are consistent with our work to deliver more productive and sustainable solutions for agriculture.
-Tom Adams, Vice President and Biotechnology Lead for Monsanto (now Bayer)
[Ontera] has developed a fascinating technology that really offers the promise of point-of-care liquid biopsy. I’m looking forward to its future potential in many different clinical capacities, including in the oncology arena. I and others in the cancer research field are tremendously excited about this approach.
-Andrew Ko, MD, Professor of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center